<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="341">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227967</url>
  </required_header>
  <id_info>
    <org_study_id>10-I-0210</org_study_id>
    <secondary_id>10-I-0210</secondary_id>
    <secondary_id>IRC003</secondary_id>
    <nct_id>NCT01227967</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications</brief_title>
  <acronym>IRC003</acronym>
  <official_title>A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seasonal influenza is responsible for many hospitalizations and deaths each year, despite
      effective antiviral treatments. Some individuals have medical conditions such as heart or
      lung diseases that make them particularly at risk of severe influenza infections that may
      result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu,
      but there are still many hospitalizations, complications, and deaths even with treatment.
      This study will evaluate the use of combination antivirals (amantadine, oseltamivir, and
      ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seasonal influenza is responsible for approximately 226,000 excess hospitalizations annually
      and despite effective antivirals causes significant morbidity and mortality (estimated
      24,000-50,000 deaths each year in the United States alone). The influenza virus that emerged
      in 2009 (A/California/07/2009 H1N1) caused fewer deaths (12,000 flu-related deaths in the
      U.S) but in contrast to seasonal flu, nearly 90 percent of the deaths with the 2009 H1N1
      occurred among people younger than 65 years of age. The CDC has defined an at-risk
      population that is responsible for the majority of hospitalization and morbidity associated
      with influenza. This study will evaluate the use of combination antivirals as compared to
      oseltamivir alone in the treatment of influenza in an at-risk population.

      Subjects who meet the CDC definition for being at-risk and that present with an
      influenza-like illness will be screened for the study. Those subjects with a confirmatory
      test for influenza (rapid antigen or PCR) will be randomized in a 1:1 manner to receive a
      blinded study treatment consisting of either the combination of amantadine, oseltamivir, and
      ribavirin or oseltamivir alone for 5 days. Clinical, virologic, and laboratory assessments
      on Days 1, 3, 7, 14, and 28 will be used for both safety and efficacy analysis.

      Objectives:

      - To evaluate the effectiveness of combined treatment with oseltamivir, amantadine, and
      ribavirin compared with oseltamivir alone for at-risk individuals with confirmed influenza
      infection.

      Eligibility:

      - Individuals at least 18 years of age who have one or more medical conditions that may
      cause complications from influenza, and have developed an influenza-like illness.

      Design:

        -  Participants will be screened with a physical examination and medical history, along
           with blood tests and throat swabs to confirm influenza infection.

        -  Eligible participants will be randomly assigned to take either oseltamivir alone (the
           current standard treatment for influenza) or to take oseltamivir, amantadine, and
           ribavirin. Participants will have additional blood samples and throat swabs taken at
           the start of the study, and will be shown how to complete a study diary at home.

        -  Participants will receive a study medication kit containing the medication to take at
           home twice a day for 5 days.

        -  Participants will return, with the medication kit, to the clinic on days 1 (the first
           day after the start of the study), 3, 7, 14, and 28. The first visit may take 2 to 3
           hours, but each subsequent visit should take approximately 1 to 2 hours. Additional
           blood samples and throat swabs will be taken at these visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate the reproducibility of virologic samples, comparison between culture and PCR, and the impact of missing data between randomized groups.</measure>
    <time_frame>First 50 subjects</time_frame>
    <safety_issue>No</safety_issue>
    <description>The specific measure used for the primary endpoint will be determined by a pilot study of the first 50 subjects randomized which will evaluate the reproducibility of virologic samples, comparison between culture and PCR, and the impact of missing data between randomized groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amantadine, Ribavirin, Oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oseltamivir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine, Ribavirin, Oseltamivir</intervention_name>
    <description>One capsule of Oseltamivir 75 mg x 2 - Total dose: 150 mg/day for 5 days; Three capsules of Ribavirin 200 mg for total of 600 mg x 2 - Total dose: 1200 mg/day for 5 days; One capsule of Amantadine 100 mg x 2 Total dose: 200 mg/day for 5 days</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>75 mg x 2 Total dose: 150 mg/day for 5 days</description>
    <arm_group_label>Oseltamivir monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Enrollment (Screening)

          1. Signed informed consent prior to initiation of any study procedures

          2. Age greater than or equal to 18 years of age

          3. Presence of an underlying medical condition(s) that may increase risk of
             complications from influenza

          4. History of an influenza-like illness defined as:

               -  One or more respiratory symptom (cough, sore throat, or nasal symptoms) AND

               -  Either

               -  Fever (subjective or documented &gt;38 degrees C) OR

               -  1 or more constitutional symptom (headache, malaise, myalgia, sweats/chills or
                  fatigue)

          5. Onset of illness no more than 96 hours before screening defined as when the subject
             experienced at least one respiratory symptom, constitutional symptom, or fever

          6. Willingness to have samples stored

        Randomization

          1. Signed informed consent

          2. Age greater than or equal to 18 years of age

          3. Presence of a medical condition(s) that have been associated with increased risk of
             complications from influenza

               -  Age 65 years of age or older

               -  Asthma

               -  Neurological and neuro-developmental conditions (including disorders of the
                  brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy,
                  epilepsy [seizure disorders], stroke, moderate to severe developmental delay,
                  muscular dystrophy, or spinal cord injury) [though still able to provide
                  informed consent per inclusion criteria #1]

               -  Chronic lung disease (such as COPD and cystic fibrosis)

               -  Heart disease (such as congenital heart disease, congestive heart failure, and
                  coronary artery disease)

               -  Blood disorders (excluding genetic causes of anemia, as noted in the exclusion
                  criteria)

               -  Endocrine disorders (such as diabetes mellitus)

               -  Kidney disorders

               -  Liver disorders

               -  Metabolic disorders (such as inherited metabolic disorders and mitochondrial
                  disorders)

               -  Weakened immune system due to disease or medication (such as people with
                  HIV/AIDS, or cancer, chronic steroids or other medications causing immune
                  suppression)

               -  BMI ≥ 40

          4. Onset of illness no more than 96 hours before screening defined as when the subject
             experienced at least one respiratory symptom, constitutional symptom, or fever

          5. Positive test for influenza (either rapid antigen or PCR)

             - Results from influenza testing obtained for clinical indications within 12 hours
             before screening/enrollment may be used if available. Randomization may proceed in
             cases of discrepant results (one positive and one negative)

          6. One of the following to avoid pregnancy:

               -  Females who are able to become pregnant (i.e., are not postmenopausal, have not
                  undergone surgical sterilization, and are sexually active with men) must agree
                  to use at least 2 effective forms of contraception from the date of informed
                  consent through 6 months after the last dose of study drug. At least one of the
                  methods of contraception should be a barrier method

               -  Males who have not undergone surgical sterilization and are sexually active with
                  women must agree to use condoms plus have a partner use at least one additional
                  effective form of contraception from the date of informed consent through 6
                  months after the last dose of study drug

          7. Willingness to have samples stored

        EXCLUSION CRITERIA:

        (for Enrollment or Randomization)

          1. Women who are pregnant or breast-feeding, and men whose female partner(s) is pregnant

          2. Inability to take oral medication or a history of gastrointestinal malabsorption that
             would preclude the use of oral medication.

          3. Hemoglobin &lt; 10 g/dL

          4. WBC &lt; 1.5 times 10(9)/L

          5. Neutrophils &lt; 0.75 x 10(9)/L

          6. Platelets &lt; 50 x 10(9)/L

          7. History of genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia)
             or autoimmune hemolytic anemia

          8. Received more than 2 doses of any antiviral influenza medications since onset of
             influenza symptoms

          9. Received stavudine (d4T), didanosine (ddI), zidovudine (AZT), or azathioprine within
             30 days prior to study entry

         10. Creatinine clearance less than 50 mL/min (estimated by the Cockcroft-Gault equation
             using serum creatinine)

         11. History of autoimmune hepatitis

         12. Uncompensated liver disease (defined as AST &gt; 3 times site upper limit of normal
             (ULN), ALT &gt; 3 times ULN, or Direct Bilirubin &gt; 2 times ULN)

         13. Clinical signs of end-stage liver disease including jaundice, coagulopathy, portal
             hypertension, esophageal varices, ascites, peripheral edema, gastrointestinal
             bleeding, or encephalopathy

         14. Chronic liver disease categorized as Child-Pugh class C (Child-Pugh score 10-15)

         15. Known hypersensitivity to rimantadine, amantadine, ribavirin, oseltamivir, peramivir,
             or zanamivir

         16. Received live attenuated virus vaccine (influenza or other) within 3 weeks prior to
             study entry

         17. Use of any investigational drug within 30 days or 5 half-lives (whichever is longer)
             prior to study entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Beigel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leidos Biomedical Research, Inc. in support of Clinical Research Section, LIR, NIAID, Natinal Institutes of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Treanor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester, School of Medicine and Dentistry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Recruitment and Public Liaison Office</last_name>
    <phone>(800) 411-1222</phone>
    <email>prpl@mail.cc.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>TTY</last_name>
    <phone>1-866-411-1010</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Simon Williamson Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Thomas Lenzmeier Family Practice</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Caldron</last_name>
      <phone>623-295-1711</phone>
      <email>mcaldron@crastudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WCCT Global LLC</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Advanced Rx Clinical Research</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Huynh</last_name>
      <phone>714-554-8080</phone>
      <email>dlhuynh@advancedrxclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute, Inc.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis M. Mendez, BS</last_name>
      <phone>323-343-8283</phone>
      <email>lmendez@usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Kunkell, RN</last_name>
      <phone>619-543-8080</phone>
      <email>jkunkell@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westlake Medical Research (CA)</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles BioMedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Babinski</last_name>
      <phone>352-213-9924</phone>
      <email>babina@shands.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Best Quality Research Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical Consulting Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Ramirez</last_name>
      <phone>305-631-6704</phone>
      <email>eramirez@suncoastresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>DMI Research, Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze &amp; Itch Associates, LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ridge Family Practice</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylie Scheideler</last_name>
      <phone>712-352-0423</phone>
      <email>kyliescheideler@crastudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Winokur</last_name>
      <phone>319-384-1735</phone>
      <email>patricia-winokur@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Integrity, LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Horizon Research Group, of Opelousas, LLC</name>
      <address>
        <city>Eunice</city>
        <state>Louisiana</state>
        <zip>70535</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Boudreaux</last_name>
      <phone>337-457-8841</phone>
      <email>rachael@horizonresearchgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies Inc. - Dr. Seep</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Charles</last_name>
      <phone>337-244-6374</phone>
      <email>lcharles@centexstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddharth Parmar, M.D.</last_name>
      <phone>617-525-8466</phone>
      <email>sparmar@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josalyn Cho</last_name>
      <phone>617-726-1721</phone>
      <email>jlcho@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMass Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celia Hartigan, RN</last_name>
      <phone>508-856-2800</phone>
      <email>celia.hartigan@umassmed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Massey, RN, BS, CCRP</last_name>
      <phone>269-341-8774</phone>
      <email>masseyg@bronsonhg.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Florissant Internists</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage/ Skyline Medical Center</name>
      <address>
        <city>Elkhorn</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Patrick Fitzgibbons, M.D.</last_name>
      <phone>402-393-2727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prairie Fields Family Medicine</name>
      <address>
        <city>Freemont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shayla Addison</last_name>
      <phone>402-753-6034</phone>
      <email>shaylaaddison@crastudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Family Physicians</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Mitchell</last_name>
      <phone>402-505-4497</phone>
      <email>JanMitchell@crastudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>James J. Peters, VA Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Aberg, MD</last_name>
      <phone>212-824-7714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina-Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Marcus</last_name>
      <phone>919-843-8761</phone>
      <email>cjm@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameron Wolfe, MD</last_name>
      <phone>919-970-3885</phone>
      <email>cameron.wolfe@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Dr. Panuto</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amie Demming</last_name>
      <phone>440-340-9010</phone>
      <email>ademming@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Quinn</last_name>
      <phone>215-349-8092</phone>
      <email>joseph.quinn@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marty Beasley</last_name>
      <phone>605-348-4141</phone>
      <email>healthconcepts104@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Dr. Bart</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Harris</last_name>
      <phone>931-255-0177</phone>
      <email>bharris@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Dr. Slandzicki</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Adamson</last_name>
      <phone>615-577-4017</phone>
      <email>dadamson@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Dr. Hoppers</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Arnold</last_name>
      <phone>731-431-5027</phone>
      <email>aarnold@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Dr. Rowe</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Adamson</last_name>
      <phone>615-693-9742</phone>
      <email>aadamson@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Dr. Dar</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Adamson</last_name>
      <phone>615-577-4017</phone>
      <email>aadamson@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Tech Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joann Urben</last_name>
      <phone>806-354-5582</phone>
      <email>joann.urben@ttuhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>3rd Coast Research Associates</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Winnie, M.D.</last_name>
      <phone>361-288-4668</phone>
      <email>mwinnie@3cra.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies Inc. - Dr. Pouzar</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shruti Konda</last_name>
      <phone>281-282-0808</phone>
      <email>skonda@centexstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Texas at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Tech HSC</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centex Studies Inc. - Dr. Garcia</name>
      <address>
        <city>Pharr</city>
        <state>Texas</state>
        <zip>78577</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma Sanchez</last_name>
      <phone>956-342-2626</phone>
      <email>nsanchez@centexstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bandera Family Healthcare Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Ceniceros</last_name>
      <phone>210-949-0807</phone>
      <email>dceniceros@endeavorct.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Platense</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Houssay</name>
      <address>
        <city>Vicente Lopez</city>
        <state>Provincia de Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centro de Educación Médica e Investigaciónes Clínicas (CEMIC)</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fundación del Centro de Estudios Infectológicos (FUNCEI)</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos J. M. Ramos Mejía</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Rawson</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instituto Centralizado de Asistencia e Investigación Clínica Integral (CAICI)</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Med Practice</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Northside Clinic</name>
      <address>
        <city>Fitzroy North</city>
        <state>Victoria</state>
        <zip>3068</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición (INCMN) Salvador Zubirán</name>
      <address>
        <city>México City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Astudillo, MD</last_name>
      <phone>(52-55) 5487-0900</phone>
      <phone_ext>2420</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Itzel Cruz, MD</last_name>
      <phone>(52-55) 5487-0900</phone>
      <phone_ext>2420</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital General y de Alta Especialidad &quot;Dr. Manuel GEA Gonzalez&quot;</name>
      <address>
        <city>Tlalpan</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias (INER)</name>
      <address>
        <city>Tlalpan</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Romo Garcia, MD</last_name>
      <phone>52 (55) 5487-1700</phone>
      <phone_ext>5295</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Roberto Sanchez, MD</last_name>
      <phone>52 (55) 5487-1700</phone>
      <phone_ext>5295</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winai Ratanasuwan, MD</last_name>
      <phone>+66-24-197-388</phone>
      <email>srwrt@mahidol.ac.th</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIV-NAT, The Thai Red Cross AIDS</name>
      <address>
        <city>Patumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anchalee Avihingsanon</last_name>
      <phone>+66-26-523-040</phone>
      <phone_ext>107</phone_ext>
      <email>anchalee.a@hivnat.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital, Khon Kaen University</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ploenchan Chetchotisakd, MD</last_name>
      <phone>+66-43-363-168</phone>
      <email>ploencha@kku.ac.th</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Muang</city>
        <state>Nonthaburi</state>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weerawat Manosuthi</last_name>
      <phone>+66-25-903-632</phone>
      <email>drweerawat@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Mexico</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2010-I-0210.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179-86.</citation>
    <PMID>12517228</PMID>
  </reference>
  <reference>
    <citation>Monto AS. Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis. 2006 Jan;12(1):55-60.</citation>
    <PMID>16494718</PMID>
  </reference>
  <reference>
    <citation>Moscona A. Oseltamivir resistance--disabling our influenza defenses. N Engl J Med. 2005 Dec 22;353(25):2633-6.</citation>
    <PMID>16371626</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 2, 2015</lastchanged_date>
  <firstreceived_date>October 22, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adaptive Design</keyword>
  <keyword>At Risk</keyword>
  <keyword>H1N1</keyword>
  <keyword>Synergy</keyword>
  <keyword>TCAD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
